JaLCDOI 10.18926/AMO/56459
FullText URL 73_1_61.pdf
Author Tamefusa, Kosuke| Ishida, Hisashi| Washio, Kana| Ishida, Toshiaki| Morita, Hirosuke| Shimada, Akira|
Abstract Patients with multi-system (MS)-type langerhans cell histiocytosis (LCH) show poor outcomes, especially congenital MS LCH cases were shown in high mortality rate. We experienced a congenital case of MS LCH with high risk organs, who needed intensive respiratory support after birth. Even though intensive chemotherapy was discontinued, this patient’s lung LCH lesions gradually became reduced and his respiratory condition recovered; therefore, we restarted and completed maintenance chemotherapy. The patient maintained complete remission for more than 4 years after the end of chemotherapy. Our case suggests that congenital MS LCH even with severe organ involvement can be treated successfully with chemotherapy.
Keywords Langerhans-cell histiocytosis congenital multisystem type
Amo Type Case Report
Published Date 2019-02
Publication Title Acta Medica Okayama
Volume volume73
Issue issue1
Publisher Okayama University Medical School
Start Page 61
End Page 65
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
JaLCDOI 10.18926/AMO/56250
FullText URL 72_5_515.pdf
Author Kanamitsu, Kiichiro| Chayama, Kousuke| Washio, Kana| Yoshida, Ryuichi| Umeda, Yuzo| Yagi, Takahito| Shimada, Akira|
Abstract Hepatitis-associated aplastic anemia (HAAA) is an acquired bone marrow failure syndrome that develops after seronegative fulminant hepatitis. Abnormal cytotoxic T-cell activation with cytokine release is a possible pathophysiology. We present the case of a 16-month-old Japanese male who developed HAAA following living-donor liver transplantation for fulminant hepatitis. His aplastic anemia was successfully treated with immunosuppressive therapy. He had been administered tacrolimus for prophylaxis against hepatic allograft rejection. Ten years after the HAAA onset, the patient’s bone marrow was found to be slightly hypoplastic. Tacrolimus may be effective in controlling abnormal immune reactions that can cause recurrent impaired hematopoiesis.
Keywords hepatitis-associated aplastic anemia impaired hematopoiesis liver transplantation immunosuppressive therapy abnormal immune reaction
Amo Type Case Report
Published Date 2018-10
Publication Title Acta Medica Okayama
Volume volume72
Issue issue5
Publisher Okayama University Medical School
Start Page 515
End Page 518
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2018 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30369609
JaLCDOI 10.18926/AMO/55208
FullText URL 71_3_249.pdf
Author Washio, Kana| Muraoka, Michiko| Kanamitsu, Kiichiro| Oda, Megumi| Shimada, Akira|
Abstract  We diagnosed a female infant with Langerhans cell histiocytosis (LCH) who was refractory to conventional chemotherapy. She showed refractory inflammation that was complicated with hemophagocytic lymphohistiocytosis (HLH) during LCH chemotherapy; therefore, we changed the protocol to HLH2004 (dexamethasone, cyclosporine A and VP16). However, there were no signs of hematological recovery. We therefore performed cord blood transplantation with reduced-intensity conditioning, and she achieved complete remission for over 2 years. As salvage therapy for refractory LCH, hematopoietic stem cell transplantation may be a good therapeutic choice, especially when LCH is complicated with HLH.
Keywords langerhans cell histiocytosis (LCH) hemophagocytic lymphohistiocytosis (HLH) hematopoietic stem cell transplantation (HSCT) reduced-intensity conditioning (RIC) refractory
Amo Type Case Report
Published Date 2017-06
Publication Title Acta Medica Okayama
Volume volume71
Issue issue3
Publisher Okayama University Medical School
Start Page 249
End Page 254
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28655945
JaLCDOI 10.18926/AMO/54815
FullText URL 70_6_503.pdf
Author Kanazawa, Yui| Yamashita, Yuka| Fujiwara, Mitsuhiro| Muraoka, Michiko| Washio, Kana| Kanamitsu, Kiichiro| Ishida, Hisashi| Nakano, Takae| Yamada, Miho| Horibe, Keizo| Tanaka, Takehiro| Yoshino, Tadashi| Shimada, Akira|
Abstract Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10–30 of cases of non-Hodgkin lymphoma, and the ALCL99 study reported 60–75 disease-free survival; however, a relatively high relapse rate was observed (25–30 ). We report 2 patients with Stage III ALCL who relapsed 6–18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identified the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the first diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be relatively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneficial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the first diagnostic bone marrow sample.
Keywords ALCL NPM-ALK fusion lymphoma
Amo Type Case Report
Published Date 2016-12
Publication Title Acta Medica Okayama
Volume volume70
Issue issue6
Publisher Okayama University Medical School
Start Page 503
End Page 506
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 28003677
JaLCDOI 10.18926/AMO/54001
FullText URL 70_1_31.pdf
Author Hanada, Takae| Kanamitsu, Kiichiro| Chayama, Kosuke| Miyamura, Takako| Kanazawa, Yui| Muraoka, Michiko| Washio, Kana| Imada, Masahide| Kageyama, Misao| Takeuchi, Akihito| Tamai, Kei| Oda, Megumi| Shimada, Akira|
Abstract The treatment of patients with congenital leukemia is difficult and often results in a poor prognosis. We present here the case of a female child with congenital acute myeloid leukemia (AML) with t(8 ; 16) (p11 ; p13) who received chemotherapy and survived for more than 10 years without relapse. A novel MOZ-CBP chimera was found in her diagnostic sample. Although adult AML patients with MOZ-CBP have mainly been reported as having therapy-related AML and showed poor prognoses, the present case supports the idea that AML with MOZ-CBP in the pediatric population might show better prognoses.
Keywords congenital leukemia AML t(8 ; 16)(p11 ; p13) MOZ-CBP
Amo Type Original Article
Published Date 2016-02
Publication Title Acta Medica Okayama
Volume volume70
Issue issue1
Publisher Okayama University Medical School
Start Page 31
End Page 35
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26899607
Web of Sience KeyUT 000371288700004